Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASBP NASDAQ:KYNB NASDAQ:RKTO NASDAQ:SNSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$6.05+3.6%$14.28$3.31▼$1,050.36$7.87M0.17351,388 shs65,470 shsKYNBKyntra Bio$6.81$7.00$4.85▼$12.60$27.58M1.0123,510 shs3,841 shsRKTORocket One Inc. Common Stock$1.97-7.9%$0.82$0.49▼$2.45$37.69M0.895.18 million shs11.51 million shsSNSESensei Biotherapeutics$16.60+4.7%$25.55$5.60▼$36.76$22.24M-0.25201,060 shs36,794 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma-2.99%+25.05%-8.26%-85.14%-98.72%KYNBKyntra Bio+0.42%-2.01%-3.12%-0.30%+686,899,900.00%RKTORocket One Inc. Common Stock-3.60%+57.35%+192.71%+111.88%+132.66%SNSESensei Biotherapeutics-1.49%-4.80%-41.21%-48.03%+134.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$6.05+3.6%$14.28$3.31▼$1,050.36$7.87M0.17351,388 shs65,470 shsKYNBKyntra Bio$6.81$7.00$4.85▼$12.60$27.58M1.0123,510 shs3,841 shsRKTORocket One Inc. Common Stock$1.97-7.9%$0.82$0.49▼$2.45$37.69M0.895.18 million shs11.51 million shsSNSESensei Biotherapeutics$16.60+4.7%$25.55$5.60▼$36.76$22.24M-0.25201,060 shs36,794 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma-2.99%+25.05%-8.26%-85.14%-98.72%KYNBKyntra Bio+0.42%-2.01%-3.12%-0.30%+686,899,900.00%RKTORocket One Inc. Common Stock-3.60%+57.35%+192.71%+111.88%+132.66%SNSESensei Biotherapeutics-1.49%-4.80%-41.21%-48.03%+134.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASBPAspire Biopharma 1.00SellN/AN/AKYNBKyntra Bio 2.33HoldN/AN/ARKTORocket One Inc. Common Stock 2.00Hold$5.00153.81% UpsideSNSESensei Biotherapeutics 2.33Hold$46.25178.61% UpsideCurrent Analyst Ratings BreakdownLatest ASBP, SNSE, KYNB, and RKTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026SNSESensei Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/29/2026SNSESensei Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/28/2026SNSESensei Biotherapeutics Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$50.005/22/2026SNSESensei Biotherapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.004/24/2026RKTORocket One Inc. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/24/2026SNSESensei Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SNSESensei Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/20/2026ASBPAspire Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026SNSESensei Biotherapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$50.003/25/2026RKTORocket One Inc. Common Stock D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/4/2026RKTORocket One Inc. Common Stock D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASBPAspire Biopharma$10K786.50N/AN/A($54.19) per share-0.11KYNBKyntra Bio$6.44M4.28N/AN/A($4.20) per share-1.62RKTORocket One Inc. Common StockN/AN/AN/AN/A$0.40 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$14.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASBPAspire Biopharma-$24.48M-$116.67N/AN/AN/AN/AN/A-398.04%N/AKYNBKyntra Bio$183.45M$40.460.17N/AN/A2,199.13%N/A-36.71%N/ARKTORocket One Inc. Common Stock-$12.47M-$0.80N/AN/AN/AN/A-165.25%-143.61%N/ASNSESensei Biotherapeutics-$21.08M-$142.72N/AN/AN/AN/A-83.59%-256.50%8/4/2026 (Estimated)Latest ASBP, SNSE, KYNB, and RKTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ASBPAspire BiopharmaN/A-$20.57N/A-$20.57N/A$0.03 million5/15/2026Q1 2026RKTORocket One Inc. Common Stock-$0.1378-$0.17-$0.0322-$0.17N/AN/A5/15/2026Q4 2025SNSESensei Biotherapeutics-$0.62-$131.45-$130.83-$131.45N/AN/A3/30/2026Q4 2025ASBPAspire BiopharmaN/A-$1.65N/A-$478.50N/A$0.00 million3/30/2026Q4 2025SNSESensei Biotherapeutics-$4.81-$3.74+$1.07-$3.74($4.85) millionN/A3/27/2026Q4 2025RKTORocket One Inc. Common Stock-$0.1031-$0.16-$0.0569-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASBPAspire BiopharmaN/AN/AN/AN/AN/AKYNBKyntra BioN/AN/AN/AN/AN/ARKTORocket One Inc. Common StockN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASBPAspire BiopharmaN/A2.262.14KYNBKyntra BioN/A3.613.48RKTORocket One Inc. Common StockN/A3.393.39SNSESensei BiotherapeuticsN/A14.3914.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASBPAspire Biopharma19.17%KYNBKyntra Bio72.71%RKTORocket One Inc. Common Stock7.08%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipASBPAspire Biopharma5.80%KYNBKyntra Bio4.15%RKTORocket One Inc. Common Stock6.92%SNSESensei Biotherapeutics7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASBPAspire BiopharmaN/A1.30 million1.22 millionN/AKYNBKyntra Bio5704.05 million3.88 millionN/ARKTORocket One Inc. Common Stock419.13 million17.80 millionNot OptionableSNSESensei Biotherapeutics401.34 million1.25 millionNot OptionableASBP, SNSE, KYNB, and RKTO HeadlinesRecent News About These CompaniesMost and least shorted healthcare stocks with market cap up to $2B at the end of MayJune 3 at 1:47 PM | seekingalpha.comSensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder James Peyer Sells 25,000 Shares of StockJune 3 at 4:04 AM | americanbankingnews.comInsider Selling: Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Sells 25,000 Shares of StockJune 2 at 4:33 AM | insidertrades.comCantor Fitzgerald initiates coverage of Sensei Biotherapeutics (SNSE) with overweight recommendationMay 30, 2026 | msn.comCitigroup initiates coverage of Sensei Biotherapeutics (SNSE) with buy recommendationMay 24, 2026 | msn.comSensei Biotherapeutics Updates 2026 Board Reconstitution PlansMay 22, 2026 | tipranks.comMillennium management reports $89k Sensei Biotherapeutics share salesMay 17, 2026 | investing.comSensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Purchases $164,021.22 in StockMay 16, 2026 | insidertrades.comSensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | businesswire.comSensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street AnalystsMay 5, 2026 | finance.yahoo.comSensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast CancerMay 5, 2026 | businesswire.comSensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00April 28, 2026 | msn.comSensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 9, 2026 | businesswire.comSensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdateMarch 30, 2026 | businesswire.comSensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 25, 2026 | businesswire.comMerger deal renews Faeth in Sensei; Piktor brightens, stock jumpsFebruary 18, 2026 | bioworld.comBSensei Biotherapeutics stock soars after Faeth Therapeutics acquisitionFebruary 18, 2026 | investing.comSensei Biotherapeutics stock soars 230% after Faeth dealFebruary 18, 2026 | msn.comSensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private PlacementFebruary 18, 2026 | finance.yahoo.comSNSE stock surges to 21-month high – everything to know about its Faeth Therapeutics acquisitionFebruary 18, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASBP, SNSE, KYNB, and RKTO Company DescriptionsAspire Biopharma NASDAQ:ASBP$6.05 +0.21 (+3.60%) Closing price 04:00 PM EasternExtended Trading$6.00 -0.05 (-0.91%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Kyntra Bio NASDAQ:KYNB$6.81 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$6.84 +0.03 (+0.44%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Rocket One Inc. Common Stock NASDAQ:RKTO$1.97 -0.17 (-7.94%) As of 04:00 PM EasternHoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Sensei Biotherapeutics NASDAQ:SNSE$16.60 +0.75 (+4.73%) Closing price 04:00 PM EasternExtended Trading$16.60 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
